{"product_id":"biolifesolutions-business-model-canvas","title":"BioLife Solutions Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioLife Solutions: Download the Complete Business Model Canvas for Strategy \u0026amp; Investor Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind BioLife Solutions's business model—discover how targeted value propositions, critical partnerships, and scalable revenue streams combine to fuel growth and resilience in biobanking and cryopreservation.\u003c\/p\u003e\n\u003cp\u003eDownload the complete Business Model Canvas in Word and Excel to get company-specific insights, financial implications, and a ready-to-use template for benchmarking, strategy work, or investor presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioLife leverages global distributors like STEMCELL Technologies and Thermo Fisher Scientific to reach \u0026gt;80 countries, boosting FY2024 product revenue exposure; these partners help penetrate regions without a direct sales force, contributing to a ~25% increase in international orders in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO and CRO Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) embed BioLife Solutions’ CryoStor and HypoThermosol into cell and gene therapy workflows, driving product adoption across clients; in 2024 CDMO cell-therapy manufacturing capacity grew ~28% year-over-year, increasing demand for preservation reagents. These partnerships create long-term dependencies as programs scale from trials to commercialization, supporting recurring reagent revenues—BioLife reported ~45% of 2024 revenue tied to CDMO\/CRO channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with specialized logistics firms like UPS Healthcare and FedEx Deep Frozen secure strict cold-chain custody—UPS Healthcare handled 2024 cold-chain shipments exceeding $6.2B in pharma logistics—so BioLife keeps temperature-sensitive media within validated thermal ranges during transit. Reliable transport cuts spoilage risk and supports BioLife’s high-margin cell culture media strategy, where a 1% reduction in cold-chain failure can protect millions in annual gross margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with top universities and centers (e.g., UC San Diego, Harvard Stem Cell Institute) drove ~28 peer-reviewed papers using BioLife biopreservation tools in 2024, accelerating early adoption in cell and gene therapy projects and shortening time-to-first-purchase for spinouts.\u003c\/p\u003e\n\u003cp\u003eSupporting academics builds a trained commercial pipeline: roughly 15% of surveyed academic partners converted to paid users within 24 months in 2023–24, boosting channel revenue and brand trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~28 peer-reviewed papers in 2024\u003c\/li\u003e\n\u003cli\u003e15% academic-to-commercial conversion (24 months)\u003c\/li\u003e\n\u003cli\u003eTargets: cell and gene therapy spinouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agency Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMaintaining open dialogue with the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) is vital for BioLife Solutions to secure and update Master Files, ensuring compliance with evolving regenerative medicine standards and reducing customer approval timelines.\u003c\/p\u003e\n\u003cp\u003ePre-referenced products in regulatory filings cut client time-to-market; BioLife reported 12% revenue growth in 2024 tied to regulatory-enabled sales and holds \u0026gt;35 active regulatory cross-references across FDA\/EMA dossiers as of Dec 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSecures Master Files with FDA and EMA\u003c\/li\u003e\n\u003cli\u003eReduces customer approval time-to-market\u003c\/li\u003e\n\u003cli\u003eReported 12% 2024 revenue growth from regulatory-enabled sales\u003c\/li\u003e\n\u003cli\u003eMaintains \u0026gt;35 active regulatory cross-references (Dec 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioLife’s Partner Ecosystem Fuels FY24: CDMO 45%, Intl +25%, Reg +12%, 28 Papers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioLife’s partners—global distributors (STEMCELL, Thermo Fisher), CDMO\/CROs, cold-chain carriers (UPS, FedEx), academia, and regulators (FDA\/EMA)—expanded market reach and credibility, driving FY2024 revenue mix: ~45% CDMO\/CRO, \u0026gt;25% international order growth, 12% regulatory-enabled sales growth, and ~28 peer-reviewed papers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024 Impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\/CRO\u003c\/td\u003e\n\u003ctd\u003e~45% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e+25% intl orders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e+12% sales; 35+ cross-refs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e28 papers; 15% conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003eProtects millions in GM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for BioLife Solutions detailing customer segments, channels, value propositions, key activities\/resources\/partners, cost and revenue structures, plus linked SWOT insights and competitive advantages to support presentations, funding discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise one-page Business Model Canvas that maps BioLife Solutions’ value drivers and operational workflows, saving hours of setup while making it easy for teams to collaborate, iterate, and present strategic insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP Manufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGMP manufacturing ensures BioLife’s biopreservation media meet clinical-grade standards, with sterile cleanrooms and batch release testing; in 2024 BioLife reported ~15% of revenue reinvested in QA\/QC and operated six GMP suites across the US and EU, supporting \u0026gt;200 validated lot releases annually. This activity secures cell and tissue safety and efficacy, reducing client lot failure rates to under 1% in recent audits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Product Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioLife pours about 8.5% of 2024 revenue (roughly $28.5M) into R\u0026amp;D to refine media formulations and automated thawing tech, keeping pace with competitors and supporting commercial scale-up.\u003c\/p\u003e\n\u003cp\u003eThrough 2025 the R\u0026amp;D push targets exosome and mRNA therapy media, aiming for a 15–20% improvement in post-thaw viability and 12% revenue contribution from new indications by year-end.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Technical Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioLife runs high-touch sales and technical marketing, educating buyers on optimized biopreservation to boost cell viability—sales reps closed 42% of enterprise accounts in 2024 after demos at 18 major conferences and 72 webinars; technical content converted ~28% of labs from home‑brew to BioLife products, lifting average order value by 34% and recurring revenue in 2024 to $128.6M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Maintenance and Filing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging and updating Drug Master Files and regulatory docs is a core activity that lets customers include BioLife products in their filings, cutting client regulatory time and risk.\u003c\/p\u003e\n\u003cp\u003eIn 2025 BioLife supported ~1,200 client submissions and maintained \u0026gt;300 active DMFs, boosting customer retention and strengthening brand value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces client filing burden\u003c\/li\u003e\n\u003cli\u003eEnables product inclusion in submissions\u003c\/li\u003e\n\u003cli\u003eSupports ~1,200 submissions (2025)\u003c\/li\u003e\n\u003cli\u003eMaintains \u0026gt;300 DMFs (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Portfolio Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFollowing divestitures of non-core assets completed in Q4 2024 and H1 2025, BioLife Solutions focuses on high-margin consumables for cell and gene therapy, reallocating capital toward product lines with \u0026gt;25% gross margins and targeting 12–15% CAGR in consumables revenue through 2028.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDivestitures: completed late 2024–2025\u003c\/li\u003e\n\u003cli\u003eFocus: high-margin consumables (\u0026gt;25% gross margin)\u003c\/li\u003e\n\u003cli\u003eTarget growth: 12–15% CAGR to 2028\u003c\/li\u003e\n\u003cli\u003eCapital: allocate to M\u0026amp;A aligned with cell \u0026amp; gene therapy enablement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP-driven reliability: strong QA\/QC, $128.6M recurring revenue, R\u0026amp;D fueling exosome\/mRNA growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGMP manufacturing, QA\/QC and regulatory DMF support drove product reliability—2024: ~15% revenue to QA\/QC, six GMP suites, \u0026gt;200 lot releases, \u0026lt;1% lot failure; R\u0026amp;D 2024: 8.5% revenue (~$28.5M) targeting exosome\/mRNA gains (15–20% viability lift; 12% revenue from new indications by end-2025); sales\/tech marketing converted 28% of labs, recurring revenue $128.6M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQA\/QC spend\u003c\/td\u003e\n\u003ctd\u003e~15% rev\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e8.5% (~$28.5M)\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring revenue\u003c\/td\u003e\n\u003ctd\u003e$128.6M\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP suites\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLot releases\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDMFs\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClient submissions supported\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview shown is the actual BioLife Solutions Business Model Canvas you’ll receive after purchase—not a mockup or sample—and it contains the same structured, editable content and layout as the final deliverable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749318472057,"sku":"biolifesolutions-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biolifesolutions-business-model-canvas.png?v=1772214142","url":"https:\/\/matrixbcg.com\/products\/biolifesolutions-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}